{"id":"W4391303220","doi":"10.1200/jco.2024.42.4_suppl.363","title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Nivolumab; Sunitinib; Ipilimumab; Internal medicine; Renal cell carcinoma; Oncology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00147736,0.0007371749,0.001433531,0.0002758845,0.0002502454,0.0008294383,0.000690475,0.0007720102,0.002780995],"category_scores_gemma":[0.0009975058,0.0002726923,0.001540198,0.0002969676,0.0004231595,0.0005678529,0.0003160501,0.001943172,0.0004071671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009113238,"about_ca_system_score_gemma":0.0009218117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009013712,"about_ca_topic_score_gemma":0.003000488,"domain_scores_codex":[0.9996643,0.0001916398,0.00001983762,0.00004791366,0.00002673507,0.00004968325],"domain_scores_gemma":[0.9993544,0.0001661836,0.0001932304,0.00004379015,0.00002091466,0.0002214071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9412466,0.006893465,0.003089357,0.0007697931,0.001713958,0.00004729798,0.0000655855,0.001560469,0.005477181,0.00008806383,0.001111302,0.03793687],"study_design_scores_gemma":[0.6311671,0.3318205,0.02413135,0.0001267414,0.003705616,0.0002368889,0.00005993696,0.002532254,0.003473646,0.0003791875,0.002326566,0.00004018796],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944906,0.002984393,0.0001790141,0.0002102714,0.0001116204,0.0004072275,0.0005661269,0.00004518697,0.00100555],"genre_scores_gemma":[0.9960831,0.001171834,0.0003737442,0.0002367558,0.0001018703,0.0004105971,0.0006543034,0.00001015824,0.0009575008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002780995,"threshold_uncertainty_score":0.009303391,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2559667269766434,"score_gpt":0.4770844221774215,"score_spread":0.2211176952007781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}